<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01178047</url>
  </required_header>
  <id_info>
    <org_study_id>Ras-PDS-1</org_study_id>
    <nct_id>NCT01178047</nct_id>
  </id_info>
  <brief_title>Multicenter Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease</brief_title>
  <acronym>Ras-PDS-1</acronym>
  <official_title>A Multicenter, Randomized, Double-blind Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease (PD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sleep-wake disturbances (SWD) are frequent in Parkinson's disease (PD) and affect the quality&#xD;
      of life of affected patients.&#xD;
&#xD;
      Rasagiline is a potent, highly selective, irreversible, second-generation, monoamine oxidase&#xD;
      type-B (MAO-B) inhibitor with a 24h dopaminergic effect.&#xD;
&#xD;
      It is well known that dopaminergic treatment closely interacts with SWD. This study aims to&#xD;
      assess the effect of Rasagiline on SWD in PD patients. In this randomized, double-blind,&#xD;
      placebo controlled study in clinical phase IV, 60 subjects will be treated with rasagiline&#xD;
      1mg po once daily or placebo over 8 weeks. The study is planned to be conducted in 6-9 Swiss&#xD;
      centers. Questionaires will be used to assess SWDs: sleep disturbances (Parkinson's Disease&#xD;
      Sleep Scale, PDSS), daytime sleepiness (Epworth Sleepiness Scale, ESS), fatigue (Fatigue&#xD;
      Severity Scale, FSS), apathy (Apathy Evaluation Scale Self, AES-S), disability (Sheehan&#xD;
      scale) and QoL in PD patients.&#xD;
&#xD;
        -  Trial with medicinal product&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    payments stopped by grant provider&#xD;
  </why_stopped>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of rasagiline on sleep disturbances in PD patients: Parkinson's Disease Sleep Scale (PDSS)</measure>
    <time_frame>Baseline after 8 weeks of treatment</time_frame>
    <description>Efficacy of rasagiline on sleep disturbances in PD patients: Parkinson's Disease Sleep Scale (PDSS)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Rasagiline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasagiline</intervention_name>
    <description>Rasagiline: 1 mg/d p.o. or Placebo one tablet p.o. once daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Rasagiline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Probable diagnosis of Parkinson's disease according to the modified UK Parkinson's&#xD;
             Disease Society Brain Bank criteria&#xD;
&#xD;
          2. Hoehn and Yahr up to stage 3 in the off-state&#xD;
&#xD;
          3. Age = 40 years&#xD;
&#xD;
          4. On the basis of a physical examination and medical history, the patient is in the&#xD;
             investigator's opinion otherwise healthy&#xD;
&#xD;
          5. Parkinson's Disease Sleep Scale (PDSS) score = 90.&#xD;
&#xD;
          6. Patients with stable dosage of hypnotics / sedative /neuropsychiatric treatment&#xD;
             including antiParkinsonian treatment in the last 4 weeks before screening evaluation&#xD;
             and with no change foreseen during the study period. Dose adjustments can be made, but&#xD;
             no change or discontinuation of drugs.&#xD;
&#xD;
          7. Subjects must understand questionnaires in German, French or Italian&#xD;
&#xD;
          8. Provided signed informed consent&#xD;
&#xD;
          9. Females of childbearing potential must agree to utilize highly effective contraceptive&#xD;
             methods of birth control.&#xD;
&#xD;
         10. Females of child bearing potential must have a negative pregnancy test.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Diagnosis unclear or suspicion of another than Parkinson's disease&#xD;
&#xD;
          2. Patients with cognitive deficit (MMSE &lt; 26)&#xD;
&#xD;
          3. Patients who have undergone surgery for the treatment of PD&#xD;
&#xD;
          4. Patients with non-response to adequate antiParkinsonian treatment&#xD;
&#xD;
          5. History of moderate to severe hepatic insufficiency.&#xD;
&#xD;
          6. Clinically relevant or unstable vascular disease&#xD;
&#xD;
          7. History of drug or alcohol abuse (within the past 10 years)&#xD;
&#xD;
          8. Patients with a history of psychotic disorders&#xD;
&#xD;
          9. Patients with treatment resistant/recurrent major depression (HADS =19)&#xD;
&#xD;
         10. Patients with unstable dosage of antiParkinsonian or neuropsychiatric treatment in the&#xD;
             last 4 weeks before screening evaluation.&#xD;
&#xD;
         11. Concomitant use of fluoxetine, fluvoxamine, pethidine or monoamine oxidase inhibitors&#xD;
             (MAOI) during the course of the study and within 3 months prior to screening&#xD;
             evaluation. Patient may be rescreened 3 months after discontinuation of the above&#xD;
             mentioned drugs.&#xD;
&#xD;
         12. Concomitant use of dextromethorphan, ephedrine or pseudoephedrine during the course of&#xD;
             the study&#xD;
&#xD;
         13. Women who are pregnant or lactating&#xD;
&#xD;
         14. Participation in another study during or up to 30 days prior to participation in this&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Baumann, Assoc Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Neurology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital, Neurology</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurocentro, Lugano</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>August 6, 2010</study_first_submitted>
  <study_first_submitted_qc>August 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2010</study_first_posted>
  <last_update_submitted>October 3, 2012</last_update_submitted>
  <last_update_submitted_qc>October 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasagiline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

